ZHX2 and hepatocellular carcinoma: In addition, ZHX2 represses transcription of multidrug resistance mutation 1 (MDR1) (33), lipoprotein lipase (LPL) (34), lysine demethylase 2A (KMD2A) (35), and S100 calcium binding protein A14 (S100A14) (7) in HCC and thyroid cancer cells.